A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs GSK 2315698 (Primary) ; GSK 2315698 (Primary) ; GSK 2398852 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 03 Aug 2017 Planned End Date changed from 21 Sep 2020 to 1 Dec 2020.
- 03 Aug 2017 Planned primary completion date changed from 21 Sep 2020 to 1 Dec 2020.
- 03 Aug 2017 Status changed from not yet recruiting to recruiting.